Press releases

Share this press release :  facebook  twitter  linkedin  google+
Quantum Genomics begins trading in the U.S. on OTCQX   (11/07/2017 07:30)

Paris & New York, July 11, 2017

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it begins trading today on OTCQX under the symbol “QNNTF”.

U.S. investors can find financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, says:

"Trading on OTCQX will enable Quantum Genomics to provide U.S. investors with access to invest through a U.S. based, dollar denominated security. Allowing Quantum Genomics to expand its shareholder base and visibility in the U.S. market without incurring the high cost and duplicative regulatory requirements of a U.S. stock exchange listing. We look forward to being part of Quantum Genomics' continued growth and success”.

Marc Karako, Director and CFO of Quantum Genomics, added:

"Quantum Genomics is very pleased to join the group of high quality international firms in the healthcare sector already trading on OTCQX. We believe that trading on OTCQX will facilitate the access to our stock in the US market which is strategic for us, both operationally and financially”."

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.

The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.

CONTACTS

Quantum Genomics

Lionel Ségard

Chairman & Chief Executive Officer
+33 1 85 34 77 77
 

Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75

marc.karako@quantum-genomics.com

SO BANG

Francis Temman

Communication médias et scientifique

+33 6 50 92 21 56

francis.temman@orange.fr

ACTUS finance & communication (Europe)

Jean-Michel Marmillon

Press Relations

+33 1 53 67 36 73

jmmarmillon@actus.fr

Edison Advisors (U.S.)

Tirth Patel

Investor Relations

+1 (646) 653-7035

tpatel@edisongroup.com



Powered by Actusnews Wire (press release services) ©